An experimental antiviral drug, called favipiravir, is still in early stages in West Africa, and too few people have been treated to really know whether the drug helps shows some promise in the fight against Ebola in West Africa. It is only effective, however, if patients get it early. The survival rate of 85% in the ones who have received it is encouraging. European Commission for Research Moedas:
If these results are confirmed by the ongoing clinical trial, it will be the first-ever treatment to be deployed against this deadly disease during the current outbreak.